User:Tblountgsu/test

Flagship Ventures is a venture capital firm located at Kendall Square in Cambridge, Massachusetts. The firm's investments focus on three business sectors: Therapeutics, Life Science Tools & Diagnostics, and Bioenergy. It was founded in 2000 and currently manages of $600 million in early-stage funds.

Investing
Flagship Ventures' team works to find the most profitable venture. The team works through three phases: design and test, build and refine, grow and harvest. The partnership of venture investment and venture creation is paramount to Flagship Venture's goal as an investment firm. The investments range from $250 thousand to $5 million, but the average investment of around $2.5 million to $4 million. Flagship Ventures can be expected to invest about $15 to $20 million during a partnership with said venture. The firm uses their investment techniques to further technological breakthroughs and commercial expansions. Generally the lead investor, Flagship Ventures focuses on ventures that are first in their category. Flagship Ventures works in coalition with entrepeneurs to create their vision. This generally entails assembling a management team and advisors to take the business further.

Team
Noubar Afeyan, PhD, Managing Partner and CEO

Noubar Afeyan recieved his Ph.D. in Biochemical Engineering from Massachusetts Institute of Technology in 1987. Dr. Noubar Afeyan has co-founded and assisted in building around 20 successful life science and technology ventures in the past twenty years. Dr. Afeyan has served as the managing head of many companies such as, Perceptive Biosystems, Applera, and Celera Genomics. Dr. Afeyan is on many prestigious boards including but not limited to, the Whitehead Institute at MIT, the SKOLKOVO School of Managment in Moscow, the Board of Overseers of Boston University, and the National Competitiveness Foundation of Armenia. In 2008, Dr. Afeyan received an Ellis Island Medal of Honor. This award is granted based on outstanding achievement for maintaining cultural intergrity while intergrating in all areas of American life.

Ed Kania, Managing Partner and Chairman

Doug Cole, MD, General Partner

Jim Matheson, General Partner

Harry Wilcox, Cheif Financial Officer and Partner

Brian Baynes, PhD, Partner

David Berry, MD, PhD, Partner

Doug Levinson, PhD, Partner

Steve Ricci, Senior Partner

Geoff von Maltzahn, New Venture Pricipal

Ann DeWitt, PhD, Senior Associate

Geoff Whitehead, PhD, Senior Associate

Dick Farrahar, Senior VP, Executive Operations

Greg Sizczkiewicz, PhD, JD, VP, Intellectual Property

Kelly Friendly, Director of Marketing

Current Companies

 * Acceleron Pharma
 * Accuri Cytometers
 * Advanced Electron Beams
 * Affinnova
 * Agios Pharmaceuticals
 * Alvine Pharmaceuticals
 * Avedro
 * AVEO Pharmaceuticals
 * BG Medicine
 * BIND Biosciences
 * Black Duck Software
 * CoNCERT Pharmaceuticals
 * Eleven Biotherapeutics
 * Ensemble Therapeutics
 * Everyday Solutions
 * Genstruct
 * Helicos BioSciences
 * INTIO
 * Joule Unlimited
 * LS9
 * Mascoma
 * Novomer
 * Oasys Water
 * Pervasis Therapeutics
 * Quanterix
 * Receptos
 * Resolvyx Pharmaceuticals
 * Seahorse Bioscience
 * Selecta Biosciences
 * Seventh Sense Biosystems
 * T2 Biosystems
 * TARIS Biomedical
 * TetraPhase Pharmaceuticals
 * Theracrine
 * TransMedics
 * Visterra
 * Ze-gen

Predecessor Funds Companies

 * Brainshark
 * Carbon Design Systems
 * DataCore Software
 * Debt Exchange
 * Kovio
 * Maptuit
 * Netuitive
 * Polatis
 * ZoomInfo

Liquidity Events

 * Adolor
 * Adnexus Therapeutics
 * Alere Medical
 * Anesta
 * Antigenics
 * Aspect Medical Systems
 * AudioLogic
 * Celera
 * CGI Pharmaceuticals
 * ChemGenics Pharmaceuticals
 * Color Kinetics
 * CombinatoRx
 * Cytyc
 * DataSage
 * Exact Sciences
 * Helicos BioSciences
 * Hypnion
 * IDEXX
 * Insmed
 * Interactive Supercomputing
 * Morphotek
 * Ontogeny
 * PerSeptive Biosystems
 * Renovis
 * Somatogen
 * TripAdvisor
 * VisEn

In The News
Flagship Ventures holds the largest investment, 45%, in BG Medicine which received FDA clearance on a new test to monitor patience with chronic heart failure in late 2010. It is the first cardiac tool in the past five years to be approved for sale by the FDA.

In October, 2010, Acceleron Pharma Inc., backed by Flagship Ventures, cut 40% percent of its employees. The company's focus is therapies to treat musculoskeletal, metabolic, and cancer-related diseases. Two drugs currently being explored by the venture are anemia and Duchenne muscular dystrophy treatments.